Clinical Trials

At Texas Heart Institute
Texas Heart Institute App Clinical Research
Menu
Current Clinical Trials

ALIVE Trial (NCT02931240)

Clinical Study of the BioVentrix Revivent System for Treatment of Left Ventricular Aneurysms (ALIVE)

A prospective, multi-center, dual-arm pivotal study of the BioVentrix Revivent TC System.  The Revivent TC System is indicated for patients referred for surgical treatment of left ventricular scar that is contiguous and includes both anterior and septal components. (Learn More)

PI: Samar Sheth, MD

ANTHEM-HFrEF Pivotal Study (NCT03425422)

Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure With Reduced Ejection Fraction

A multi-center randomized controlled clinical trial to evaluate Autonomic Regulation Therapy with the VITARIA system in patients with symptomatic heart failure and reduced ejection fraction.

PI: Joggy George, MD

CardiAMP™ Heart Failure Trial (NCT02438306)

Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy system in Patients with Post Myocardial Infarction Heart Failure

A clinical trial for patients suffering from heart failure after a previous heart attack.

PI: Emerson Perin, MD, PhD
SPONSOR: BioCardia, Inc

CHIEF HF Study (NCT04252287)

Canagliflozin: Impact on Health Status, Quality of Life, and Functional Status in Heart Failure

The purpose of this study is to determine the superiority of the effectiveness of canagliflozin 100 milligram (mg) daily versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS).

PI: Emerson Perin, MD, PhD
Sponsor: Janssen Research & Development, LLC

Refer a Patient

cVAD Study

Ongoing, observational, prospective, multicenter, records review study of routine clinical care and outcomes for patients who received support from one or multiple ABIOMED, Inc. hemodynamic support devices in routine clinical care.

PI: Andrew Civitello, MD

GORE EXCLUDER (NCT02489539)

Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

A study to assess the safety and effectiveness of the GORE® EXCLUDER® Conformable AAA Endoprosthesis to treat an infrarenal aneurysm located in the abdominal aorta.

PI: Zvonimir Krajcer, MD
SPONSOR: W.L.Gore & Associates

 

Heart FID (NCT03037931)

Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency

PI: Reynolds Delgado, MD

Stem Cell Therapy vs Standard of Care in Cardiomyopathy (NCT02962661)

Randomized 3-Arm Trial with Standard of Care Alone vs either Intravenous Infusion or Transendocardial Injection of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) plus Standard of Care in Patients with Anthracycline-Associated Cardiomyopathy 2015-0835

To demonstrate the safety of allogeneic human mesenchymal stem cells (hMSCs) administered by intravenous infusion and transendocardial injection in patients with left ventricular (LV) dysfunction and heart failure secondary to chemotherapy with anthracyclines.

MDA Study PI: Amanda Olson, MD
THI PI: Emerson Perin, MD, PhD
SPONSOR: M.D. Anderson Cancer Center
COLLABORATOR: Texas Medical Center

LESS-VT | FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study (NCT03490201)

This clinical investigation is intended to demonstrate the safety and effectiveness of ventricular ablation therapy using the FlexAbility Sensor Enabled Ablation Catheter in patients with drug-refractory monomorphic ventricular tachycardia in whom ventricular tachycardia recurs despite antiarrhythmic drug therapy or when antiarrhythmic drugs are not tolerated or desired.

PI: Nilesh Mathuria
SPONSOR: Abbott

Solve CRT (NCT02922036)

Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients (SOLVE CRT)

This study is a prospective, multi-center, randomized, controlled, double blinded, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy.  The WiSE-CRT System is an implantable cardiac pacing system capable of delivering pacing energy to the left ventricle of the heart without using a pacing lead.

PI: Nilesh Mathuria, MD
SPONSOR: EBR Systems

PORTICO IDE (NCT02000115)

The PORTICO clinical trial is a prospective, multi-center, randomized, controlled clinical study, designed to evaluate the safety and effectiveness of the SJM Portico Transcatheter Heart Valve and Delivery Systems (Portico) via transfemoral and alternative delivery methods.